{"ticker": {"uuid": "930fc8d2-c796-430e-b622-91485e13c8d9", "symbol": "IMMX", "name": "Immix Biopharma Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Immix Biopharma Inc. (IMMX) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live stock price information and charts for Immix Biopharma Inc. (IMMX), showing its current price of $10.52, a decrease of $0.16 (-1.50%). It also indicates that there are currently no analyst ratings or earnings information available for the company. The page", "url": "https://www.timothysykes.com/quote/IMMX/", "source_name": "www.timothysykes.com", "published_at": "2026-07-14T22:39:58", "published_display": "14 Jul 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Immix Biopharma\u2019s Big Run Rests On Early CAR-T Data", "summary": "Immix Biopharma (NASDAQ: IMMX) has experienced a significant 310% stock jump over the past year, driven by positive early data from its NXC-201 CAR-T therapy for AL amyloidosis and multiple myeloma. The company's valuation is highly reliant on clinical advancements, regulatory de", "url": "https://finimize.com/content/immx-asset-snapshot", "source_name": "Finimize", "published_at": "2026-07-12T18:41:23", "published_display": "12 Jul 2026 18:41", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Immix Biopharma, Inc. \u2013 NASDAQ:IMMX", "summary": "This article provides financial information for Immix Biopharma, Inc. (NASDAQ: IMMX), specifically focusing on its enterprise value to forward revenue. It appears to be an entry from a financial data platform, presenting a metric and linking to further financial and company detai", "url": "https://www.tradingview.com/symbols/NASDAQ-IMMX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T12:40:05", "published_display": "08 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Immix Biopharma, Inc. \u2013 NASDAQ:IMMX", "summary": "The article displays the \"Price to book forward\" for Immix Biopharma, Inc. (NASDAQ: IMMX). It is presented as a financial data point within the TradingView platform, indicating a specific period, value, and percentage change.", "url": "https://www.tradingview.com/symbols/NASDAQ-IMMX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T12:13:50", "published_display": "07 Jul 2026 12:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma, Inc. Financial Disclosures & SEC Filings", "summary": "This article provides a comprehensive list of Immix Biopharma, Inc.'s SEC filings and other corporate documents, including earnings reports and corporate presentations, from 2021 to 2026. It highlights key financial performance updates, clinical progress for NXC-201, and details ", "url": "https://www.tradingview.com/symbols/BOATS-IMMX/documents/", "source_name": "TradingView", "published_at": "2026-07-05T03:11:07", "published_display": "05 Jul 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Immix Biopharma, Inc. \u2013 NASDAQ:IMMX", "summary": "This article provides the \"Price to sales forward\" metric for Immix Biopharma, Inc. (NASDAQ: IMMX), noting that the market was closed with no trades when this information was accessed. It highlights financial data presented on TradingView without specifying the actual value.", "url": "https://www.tradingview.com/symbols/NASDAQ-IMMX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T15:11:07", "published_display": "04 Jul 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Immix Biopharma, Inc. \u2013 NASDAQ:IMMX", "summary": "This article displays the \"Price to earnings forward\" value for Immix Biopharma, Inc. (NASDAQ: IMMX) on the TradingView platform. It presents financial data for the company and is part of a larger market analysis tool.", "url": "https://www.tradingview.com/symbols/NASDAQ-IMMX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T10:09:03", "published_display": "04 Jul 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma, Inc. Actuals & Estimates (NASDAQ:IMMX)", "summary": "This article provides details on Immix Biopharma, Inc. (NASDAQ: IMMX) stock performance, analyst estimates, and financial data. It covers the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings reports, alongside other financia", "url": "https://www.tradingview.com/symbols/NASDAQ-IMMX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:39:09", "published_display": "26 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Immix Biopharma, Inc. (IMMX) stock, based on analyst opinions. It includes current stock performance metrics, historical price data, financial statistics like market capitalization and earnings, and information on future earni", "url": "https://www.tradingview.com/symbols/NASDAQ-IMMX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:10:39", "published_display": "25 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "All You Need to Know About Immix Biopharma (IMMX) Rating Upgrade to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNTHVEekRFenBhdDBrT2Jiam55MDctdlZTZXhNUDBsc20xdndfZHhmWDFGSm1GVjgwU05KLWgydEZNSmU1cGdQLUZzVFdGTExRZmNsZHB4aFVJNzN6WkM4NThBeGN4amJzZElldG9JOWM5OHY3TWx1RTZOM0lQMGcwRW0yVWFjRmJhQktjMTNFTmRZQ3VlazNTX2JoUFo5QQ?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA initiates Immix Biopharma stock with buy rating on AL amyloidosis drug", "summary": "BofA Securities has initiated coverage on Immix Biopharma (NASDAQ:IMMX) with a Buy rating and a $27 price target, citing the potential of its NXC201 drug for AL amyloidosis. The drug has shown promising early data with a 95% complete response rate and a favorable safety profile. ", "url": "https://ng.investing.com/news/stock-market-news/bofa-initiates-immix-biopharma-stock-with-buy-rating-on-al-amyloidosis-drug-93CH-2564891", "source_name": "Investing.com Nigeria", "published_at": "2026-06-19T10:39:33", "published_display": "19 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 81, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA Securities Initiates Immix Biopharma(IMMX.US) With Buy Rating, Announces Target Price $27", "summary": "BofA Securities has initiated coverage on Immix Biopharma (IMMX.US) with a Buy rating. The firm also announced a target price of $27 for the biopharmaceutical company. This indicates BofA's positive outlook on Immix Biopharma's stock.", "url": "https://www.moomoo.com/news/post/71729959/bofa-securities-initiates-immix-biopharma-immxus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-06-19T09:10:24", "published_display": "19 Jun 2026 09:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions", "summary": "Bank of America Securities initiated coverage on Immix Biopharma (NASDAQ: IMMX) with a Buy rating and a $27 price target, citing strong clinical data for NXC-201 in AL amyloidosis. The analyst models worldwide risk-adjusted peak sales of $963 million for NXC-201, which has shown ", "url": "https://www.benzinga.com/analyst-stock-ratings/initiation/26/06/53286177/immix-biopharma-analyst-bullish-but-flags-safety-adoption-questions", "source_name": "Benzinga", "published_at": "2026-06-18T17:09:47", "published_display": "18 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet", "summary": "Wall Street analysts project that Immix Biopharma (IMMX) could see a 113.58% surge, with a mean price target of $19.5. While consensus price targets should be treated with skepticism due to analysts' potential biases, the recent positive trend in earnings estimate revisions and a", "url": "https://finance.yahoo.com/markets/stocks/articles/wall-street-analysts-think-immix-135502769.html", "source_name": "Market source", "published_at": "2026-06-18T13:55:00", "published_display": "18 Jun 2026 13:55", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma, Inc. Stock 12\u2011Month Price Target Raised to $19.79, Implies 117% Upside", "summary": "Immix Biopharma, Inc. (IMMX) has seen its average price target raised to $19.79 from $18.58 by 7 analysts, with forecasts ranging from $14.50 to $27.00 per share. This updated target implies a potential upside of approximately 117% based on the June 17 closing price. The consensu", "url": "https://www.tradingview.com/news/tradingview:dcc1b5058a319:0-immix-biopharma-inc-stock-12-month-price-target-raised-to-19-79-implies-117-upside/", "source_name": "TradingView", "published_at": "2026-06-18T13:09:47", "published_display": "18 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 92, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA Initiates Immix Biopharma at Buy With $27 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/bofa-initiates-immix-biopharma-buy-115517876.html", "source_name": "MT Newswires", "published_at": "2026-06-18T11:55:17+00:00", "published_display": "18 Jun 2026 11:55", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma Inc (IMMX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Immix Biopharma Inc (IMMX), highlighting analyst ratings, target prices, and past EPS performance. Five analysts currently rate IMMX as a \"Buy\" with a target price of $21.00, suggesting a 130.01% upside. The report also lists peer co", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-immx/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T08:40:52", "published_display": "18 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma Inc (IMMX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Immix Biopharma Inc (IMMX) focusing on its dividend history and stock splits. The data presented indicates that the company has not distributed any dividends over the past five years and has no recorded stock split history. The article also in", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-immx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T08:09:47", "published_display": "18 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma Inc (IMMX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey focuses on Immix Biopharma Inc (IMMX) and its revenue breakdown. It states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The page provides basic stock information ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-immx/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T01:09:15", "published_display": "18 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMX Initiates Coverage On LifeSci Capital -- Rating at Outperfo", "summary": "LifeSci Capital initiated coverage on Immix Biopharma (IMMX) with an \"Outperform\" rating and a $19.00 price target, suggesting significant upside from its current trading price of $9.31. Despite a low GF Score\u2122 of 30/100, indicating weaknesses in profitability and growth, IMMX bo", "url": "https://www.gurufocus.com/news/8921236/immx-initiates-coverage-on-lifesci-capital-rating-at-outperform", "source_name": "GuruFocus", "published_at": "2026-06-17T20:09:15", "published_display": "17 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma Inc (IMMX) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a brief overview of Immix Biopharma Inc's (IMMX) stock performance and valuation metrics. It notes that key valuation data such as P/E, P/B, P/S, and P/CF ratios have not yet been disclosed by the company. The article also includes current stock price inform", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-immx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T16:09:15", "published_display": "17 Jun 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma Inc (IMMX) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Immix Biopharma Inc (IMMX), analyzing its volatility, financial risk, and investment risk. It details various metrics such as Beta, VaR, Maximum Drawdown, Volatility, and Return-to-Drawdown Ratio over different periods. The purpose is t", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-immx/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-17T15:41:05", "published_display": "17 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street analysts see a 120.59% upside in Immix Biopharma (IMMX): Can the stock really move this high?", "summary": "This article discusses the significant upside potential that Wall Street analysts see in Immix Biopharma (IMMX), projecting a 120.59% price increase. It poses a question regarding the feasibility of this substantial stock movement. The content originally came from an MSN source.", "url": "https://www.msn.com/en-us/money/topstocks/wall-street-analysts-see-a-120-59-upside-in-immix-biopharma-immx-can-the-stock-really-move-this-high/ar-AA24c6vs?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-09T04:39:37", "published_display": "09 Jun 2026 04:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMX - Immix Biopharma Inc Stock Price and Quote", "summary": "This page provides a comprehensive overview of Immix Biopharma Inc. (IMMX) stock, including its latest stock price, financial data, performance metrics, and recent news and analyst ratings. It also details insider transactions, highlighting purchases by the CEO and CFO, and lists", "url": "https://finviz.com/stock?t=IMMX", "source_name": "Finviz", "published_at": "2026-06-07T04:09:51", "published_display": "07 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janus Henderson files 13G/A: 9.09M shares of Immix Biopharma (IMMX)", "summary": "Janus Henderson Group plc has filed an amended Schedule 13G/A, reporting beneficial ownership of 9,090,732 shares, or 13.0% of Immix Biopharma, Inc. (IMMX). The filing indicates that Janus Henderson's Asset Managers exercise shared voting and dispositive power over these shares, ", "url": "https://www.stocktitan.net/sec-filings/IMMX/schedule-13g-a-immix-biopharma-inc-amended-passive-investment-disclos-58e09dfc31b7.html", "source_name": "Stock Titan", "published_at": "2026-06-05T16:40:19", "published_display": "05 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma, Inc. Files Form 8-K Announcing Election of Directors and Corporate Details (May 2026)", "summary": "Immix Biopharma, Inc. (NASDAQ: IMMX) has filed its Form 8-K to announce the results of its 2026 Annual Shareholder Meeting held on May 22, 2026. Shareholders elected Ilya Rachman as a director with strong approval and ratified Crowe LLP as the independent registered public accoun", "url": "https://www.minichart.com.sg/2026/05/31/immix-biopharma-inc-files-form-8-k-announcing-election-of-directors-and-corporate-details-may-2026/", "source_name": "Minichart", "published_at": "2026-05-31T09:08:57", "published_display": "31 May 2026 09:08", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma (IMMX) director receives 6,250 RSUs and 12,500 options", "summary": "Immix Biopharma director Nancy T. Chang received equity awards totaling 6,250 restricted stock units (RSUs) and options for 12,500 shares. These awards, granted under the 2021 Equity Incentive Plan, are subject to vesting schedules tied to continued service and the company's 2027", "url": "https://www.stocktitan.net/sec-filings/IMMX/form-4-immix-biopharma-inc-insider-trading-activity-39f650a73b1e.html", "source_name": "Stock Titan", "published_at": "2026-05-30T12:10:59", "published_display": "30 May 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma (IMMX) CFO, President awarded 500,000 stock options at $8.78", "summary": "Immix Biopharma's CFO and President, Morris Gabriel S, was granted 500,000 stock options with an exercise price of $8.78 per share, expiring on May 22, 2036. The options vest in 48 equal monthly installments, linking the executive's ownership to continued service. This grant is c", "url": "https://www.stocktitan.net/sec-filings/IMMX/form-4-immix-biopharma-inc-insider-trading-activity-c6e217c25eb4.html", "source_name": "Stock Titan", "published_at": "2026-05-30T12:08:57", "published_display": "30 May 2026 12:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma (IMMX) director Carey Ng awarded RSUs, 12,500-share option", "summary": "Immix Biopharma director Carey Ng received 6,250 restricted stock units (RSUs) and a stock option for 12,500 shares. The RSUs will vest on the earlier of one year from the grant date or the 2027 annual stockholders' meeting, while the stock option vests in monthly installments ov", "url": "https://www.stocktitan.net/sec-filings/IMMX/form-4-immix-biopharma-inc-insider-trading-activity-882d4d8d6294.html", "source_name": "Stock Titan", "published_at": "2026-05-30T12:08:57", "published_display": "30 May 2026 12:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma (IMMX) awards CEO 500,000 stock options at $8.78 strike", "summary": "Immix Biopharma, Inc. (IMMX) has granted its CEO and Chairman, Ilya M. Rachman, 500,000 stock options with an exercise price of $8.78 per share, expiring on May 22, 2036. These options serve as compensation and will vest in 48 equal monthly installments, contingent on Dr. Rachman", "url": "https://www.stocktitan.net/sec-filings/IMMX/form-4-immix-biopharma-inc-insider-trading-activity-2fdd731ceef8.html", "source_name": "Stock Titan", "published_at": "2026-05-29T21:10:23", "published_display": "29 May 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNdTRSUkpvZDZJb2lMendCYlFteTlGU3hiWC1OMGlWNm1jNnZkdGJ1RVY0WFJyOG90QlBnMHFnRlhHYlhfdkhzSmhKengyS2dDeTVzbXZlOVdsbFo5TWYtNTNHLVdOQXpMOGlKb3V4dkFfV0xJMlQ0Y2UzTGxBek9hRDJpaE1rTXhieHAxeGlQVHNSN29xSVpwZ0pmNkhpMmdtSld3cVJnckNiTEs1SGd2MU1fUQ?oc=5", "source_name": "Investing News Network", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma, Inc. Closes $140.65 Million Underwritten Registered Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNa3czaUNvMzh4bG9Fd18tZTlxQnU1cXdMYld5X3RCRGtSWEZjeTlIX0s5T3A5UW1wclYtaDhIdkJmc0RjUEtxaG9CVGNIbHkybDhBMVo5Nzc4U2pzYXBrV1l2R0lib2hnX3JYbGJDTlEzOU4wbEw1UTJmT3lEa01KbzlQTDBKY0xMeWcxemVQVmdfMXdNVGZtUkpXNHNOel9CdTVzNnNMbERxWjJIckEyMk9QdWxBNU9EbDkxOHR5UzJyNXNLcklfblhn?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma Prices $150 Million Stock Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immix-biopharma-prices-150-million-110608655.html", "source_name": "MT Newswires", "published_at": "2026-05-21T11:06:08+00:00", "published_display": "21 May 2026 11:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma Reports 95% Complete Response Rate in AL Amyloidosis Trial", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/immix-biopharma-reports-95-complete-104403227.html", "source_name": "MT Newswires", "published_at": "2026-05-21T10:44:03+00:00", "published_display": "21 May 2026 10:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxORENuS0NMcWk3SjlNRy0xSnNkX0ZRQUlLbDVYT3pVb3J6V0pZQWFnUkRtN2VZOF9welVjODdGaGpRejBnVm5nZnBBRE5oRE9qbzUxaFZZcWpFTVZ1S3ZFNUNsVzZXLTlrbWs0V0QwSTNJMzFYeW44TE5Dbl9pMG9MM2VxYmZGcVlBVTFVZ1RWX3BQMzBBQ05mbW5JS0F5SWtaakk3SW51a1J4ZEVMSmwzQllldw?oc=5", "source_name": "Investing News Network", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma prices $150M deal to fund NXC-201 work into 2028", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOZFJRcFF5SHZETVluZUpnV0x3OTlXM1NDRXlvNnJtVHRpaklNRWNycnA4MWxsYjZONzRnV09fUzYxUkl5eWc4eWhFaEJoR3l5VktfTVdOM3g3cV9uRmR0VUllYU1ZVkJCdTFDeGJZRDdGWUY5akdFaVdrYVdZbVlXZFA1MWhmSDNXYk1oeWpvZUtFc2o0LWtUYUNsMWhkY1Z0b2VZYmV4TWZsMkxyT3ZMbENVQTlVdXM?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix rises after mid-stage trial data for AL amyloidosis therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPcGNReUVmcE5xZG9qcFYzbktGbTBqMFNXOVEwbnhCOVRQbWhCbUpFaktjaUxsekxJZXlLeUZJdVNhZ1lFbUh3WmlaUTR4bXNyNkZDYTBWRVluWnpRVXBpalJMWFlDaFk0YV9Hb3ZhMVNialJLUFF1c2pBSE5TVjFWaTI3VQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Immix Biopharma stock rating maintained at Market Outperform by Citizens", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQaEV5OXlVRWVMbFBtMGNxa0hreEExYUM2cnFtc0p2ZlJQTWc3dU9RaFpzdE92bGZBZzBEMjhGdmtqcld4Q3plWkRlNzN1WEJsbERDVTY4N0pycDlYVWhiaTJmNU03WHVWOEYzbXpyWmRfRzBlS1JzSTFQamZKWFZraVRZNUpTZm9BNnJKR3pkcWtFcWtNZVEyZkluMVItT2xfdmEyNjJkejZXWXJrUUl6SVROSWVicGtZWVZYS040b2VINmd4VDJTQVRQM0s?oc=5", "source_name": "Investing.com", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "We Think Immix Biopharma (NASDAQ:IMMX) Can Afford To Drive Business Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOVnVWc0UwUmljcHBnd0dHSzM1QTlUeVdGOWx1aUw5R3F0bjBLYzhwY09keVFBUG9NWUYwaWJYYnBtejNIS3QteGxSdnk2UXR6T2hJVkVYTjZjZVZqMnpxOTlJZ2RvUUx3LWd4cE5PVzJoZmRzRExZQ1RHUUxFWEV4Qmp1MHI0dGVUUElLX1dtUzVtcjZEd3dqRHloTnhnOW8?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Immix Biopharma (IMMX) One of the Best Performing NASDAQ Stocks?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNazR1UHNhcDRqRGh3cFU4eVl3ZWNrYWQ3aGxiWUpFMUVjZlBFV183XzFwRjdFZ3BlQ2FDQWNCQUFCaHhpbEZOR3NJdzJ0RDNOb2d4Nzh4OG1QU3d4YlNxSWNjR1pDMzlzeFFvVngzUkJrem9TQmp6TFlWYjRzUDNFOXhXT1ZtZmgyRktGeWJFMjk4Y2tMRWk1MFNR?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Immix Biopharma lines up investor meetings at Jefferies event", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPSWhVNXNtU1BtdDRuMVRtdElUd3FQTERqMmRjTlZSREhfc3NoYWtoaWZ3VEpWekZ0bGh1ZVAxcldEbXNPWkVHTUROVDgzMWZSald3NTRHNHNfaFNVblhjVXluQjdQRnVXaS14S2RMTnFEeW8wblFHUFl2QjhVWjNmZW9sLUlnSnY1dk5WWmlJdWl5T29QdG5MaTNROGZGOEg3TS03d2tyZFZnMHdPSFhKWHVUNVU4Z0Y1Mk4yQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix fills amyloidosis trial; Q3 results tee up planned FDA filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNTTJlOVd5ekdZeVBvcFBDNldtYUxQd0EyQWMzNS1mcWFMTmFlMFlaMEhZQ0RyLTdTZXBvZnR1WXhpOFF1WDZTVjc5d2kwdmx4dzhXT0Q1RmZMX1JCc3o3RVJUYnpIY0h3NWRGN0VTS0lyaGxsZmV6SDJXSDhOSlFjdG81LVF4d1A5WGJIRjVaMThVbF83aTY2QlJVZTdXdnFjWkdPcEpGQndwVmFHTnFLT1hEeUZIQlhjRkE?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Immix Biopharma (NASDAQ: IMMX) amends $100M at-the-market stock sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNLU12Sm1Qelg1RGVIRDNnTEVrZFJXeUtkTmdkR1JKczJIdVRnZ2hJRVl1MTU3ZGZndVZhWGtXS2pHM2kyNUtJV29DTzZFeERVSmFkbVFYVGprdWFZakYwWUlPMGNSSkNNTUlnSHlqbGhha1ZEQXhqMzdOeENEVDBQQUJPdWdmRGw0bm1mSVpEbGxxMm1WSVI5UHVvSmpyTUFLRy1PdHBhbkRaQmd2?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Expect Breakeven For Immix Biopharma, Inc. (NASDAQ:IMMX) Before Long", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma, Inc. Closes $93.7 Million Underwritten Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNZ2Z5ZkxEMTdhaVlXa2F2Rm9aZkxnS0RhdzIwZEJsbVJlSENucnFjZzZMU2lXZjEwX0d4VHlKODZKekhzQk5DUnl0djlqQkVDem16a2xnbDljYTRIY2o4WUNpRm5qY05WZ2tReFpETnNRMEpVNF9jQ25CbmM1RHNOSkF5R3NNUm1tZ0EtVWJraVJQMFpIMUZjY09OUXEyTGRuZ0sxOF80NTc3ZEZzUU9yaUJyU01mNTB3dGVuM3NGUk1hOVllbGl0VmUtUERQd01uQ3lOWFdSSjk?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma (IMMX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBzVmlWM2M0ZG12NVdnc2JONnBTTHd4a0tFSEQ5SXpOdGNLZkpEaFhOX1BWdy1kUzdmUmMtOWpkTU85aHVOR2VaSjREVzRGN1hwYVhLWVVZSjFQdw?oc=5", "source_name": "MarketBeat", "published_at": "2021-12-17T00:51:18+00:00", "published_display": "17 Dec 2021 00:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Immix Biopharma Inc. (IMMX) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live stock price information and charts for Immix Biopharma Inc. (IMMX), showing its current price of $10.52, a decrease of $0.16 (-1.50%). It also indicates that there are currently no analyst ratings or earnings information available for the company. The page", "url": "https://www.timothysykes.com/quote/IMMX/", "source_name": "www.timothysykes.com", "published_at": "2026-07-14T22:39:58", "published_display": "14 Jul 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma\u2019s Big Run Rests On Early CAR-T Data", "summary": "Immix Biopharma (NASDAQ: IMMX) has experienced a significant 310% stock jump over the past year, driven by positive early data from its NXC-201 CAR-T therapy for AL amyloidosis and multiple myeloma. The company's valuation is highly reliant on clinical advancements, regulatory de", "url": "https://finimize.com/content/immx-asset-snapshot", "source_name": "Finimize", "published_at": "2026-07-12T18:41:23", "published_display": "12 Jul 2026 18:41", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Immix Biopharma, Inc. \u2013 NASDAQ:IMMX", "summary": "This article provides financial information for Immix Biopharma, Inc. (NASDAQ: IMMX), specifically focusing on its enterprise value to forward revenue. It appears to be an entry from a financial data platform, presenting a metric and linking to further financial and company detai", "url": "https://www.tradingview.com/symbols/NASDAQ-IMMX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T12:40:05", "published_display": "08 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Immix Biopharma, Inc. \u2013 NASDAQ:IMMX", "summary": "The article displays the \"Price to book forward\" for Immix Biopharma, Inc. (NASDAQ: IMMX). It is presented as a financial data point within the TradingView platform, indicating a specific period, value, and percentage change.", "url": "https://www.tradingview.com/symbols/NASDAQ-IMMX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T12:13:50", "published_display": "07 Jul 2026 12:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma, Inc. Financial Disclosures & SEC Filings", "summary": "This article provides a comprehensive list of Immix Biopharma, Inc.'s SEC filings and other corporate documents, including earnings reports and corporate presentations, from 2021 to 2026. It highlights key financial performance updates, clinical progress for NXC-201, and details ", "url": "https://www.tradingview.com/symbols/BOATS-IMMX/documents/", "source_name": "TradingView", "published_at": "2026-07-05T03:11:07", "published_display": "05 Jul 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Immix Biopharma, Inc. \u2013 NASDAQ:IMMX", "summary": "This article provides the \"Price to sales forward\" metric for Immix Biopharma, Inc. (NASDAQ: IMMX), noting that the market was closed with no trades when this information was accessed. It highlights financial data presented on TradingView without specifying the actual value.", "url": "https://www.tradingview.com/symbols/NASDAQ-IMMX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T15:11:07", "published_display": "04 Jul 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Immix Biopharma, Inc. \u2013 NASDAQ:IMMX", "summary": "This article displays the \"Price to earnings forward\" value for Immix Biopharma, Inc. (NASDAQ: IMMX) on the TradingView platform. It presents financial data for the company and is part of a larger market analysis tool.", "url": "https://www.tradingview.com/symbols/NASDAQ-IMMX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T10:09:03", "published_display": "04 Jul 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma, Inc. Actuals & Estimates (NASDAQ:IMMX)", "summary": "This article provides details on Immix Biopharma, Inc. (NASDAQ: IMMX) stock performance, analyst estimates, and financial data. It covers the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings reports, alongside other financia", "url": "https://www.tradingview.com/symbols/NASDAQ-IMMX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:39:09", "published_display": "26 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Immix Biopharma, Inc. (IMMX) stock, based on analyst opinions. It includes current stock performance metrics, historical price data, financial statistics like market capitalization and earnings, and information on future earni", "url": "https://www.tradingview.com/symbols/NASDAQ-IMMX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:10:39", "published_display": "25 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "All You Need to Know About Immix Biopharma (IMMX) Rating Upgrade to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNTHVEekRFenBhdDBrT2Jiam55MDctdlZTZXhNUDBsc20xdndfZHhmWDFGSm1GVjgwU05KLWgydEZNSmU1cGdQLUZzVFdGTExRZmNsZHB4aFVJNzN6WkM4NThBeGN4amJzZElldG9JOWM5OHY3TWx1RTZOM0lQMGcwRW0yVWFjRmJhQktjMTNFTmRZQ3VlazNTX2JoUFo5QQ?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA initiates Immix Biopharma stock with buy rating on AL amyloidosis drug", "summary": "BofA Securities has initiated coverage on Immix Biopharma (NASDAQ:IMMX) with a Buy rating and a $27 price target, citing the potential of its NXC201 drug for AL amyloidosis. The drug has shown promising early data with a 95% complete response rate and a favorable safety profile. ", "url": "https://ng.investing.com/news/stock-market-news/bofa-initiates-immix-biopharma-stock-with-buy-rating-on-al-amyloidosis-drug-93CH-2564891", "source_name": "Investing.com Nigeria", "published_at": "2026-06-19T10:39:33", "published_display": "19 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 81, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA Securities Initiates Immix Biopharma(IMMX.US) With Buy Rating, Announces Target Price $27", "summary": "BofA Securities has initiated coverage on Immix Biopharma (IMMX.US) with a Buy rating. The firm also announced a target price of $27 for the biopharmaceutical company. This indicates BofA's positive outlook on Immix Biopharma's stock.", "url": "https://www.moomoo.com/news/post/71729959/bofa-securities-initiates-immix-biopharma-immxus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-06-19T09:10:24", "published_display": "19 Jun 2026 09:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions", "summary": "Bank of America Securities initiated coverage on Immix Biopharma (NASDAQ: IMMX) with a Buy rating and a $27 price target, citing strong clinical data for NXC-201 in AL amyloidosis. The analyst models worldwide risk-adjusted peak sales of $963 million for NXC-201, which has shown ", "url": "https://www.benzinga.com/analyst-stock-ratings/initiation/26/06/53286177/immix-biopharma-analyst-bullish-but-flags-safety-adoption-questions", "source_name": "Benzinga", "published_at": "2026-06-18T17:09:47", "published_display": "18 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet", "summary": "Wall Street analysts project that Immix Biopharma (IMMX) could see a 113.58% surge, with a mean price target of $19.5. While consensus price targets should be treated with skepticism due to analysts' potential biases, the recent positive trend in earnings estimate revisions and a", "url": "https://finance.yahoo.com/markets/stocks/articles/wall-street-analysts-think-immix-135502769.html", "source_name": "Market source", "published_at": "2026-06-18T13:55:00", "published_display": "18 Jun 2026 13:55", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma, Inc. Stock 12\u2011Month Price Target Raised to $19.79, Implies 117% Upside", "summary": "Immix Biopharma, Inc. (IMMX) has seen its average price target raised to $19.79 from $18.58 by 7 analysts, with forecasts ranging from $14.50 to $27.00 per share. This updated target implies a potential upside of approximately 117% based on the June 17 closing price. The consensu", "url": "https://www.tradingview.com/news/tradingview:dcc1b5058a319:0-immix-biopharma-inc-stock-12-month-price-target-raised-to-19-79-implies-117-upside/", "source_name": "TradingView", "published_at": "2026-06-18T13:09:47", "published_display": "18 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 92, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA Initiates Immix Biopharma at Buy With $27 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/bofa-initiates-immix-biopharma-buy-115517876.html", "source_name": "MT Newswires", "published_at": "2026-06-18T11:55:17+00:00", "published_display": "18 Jun 2026 11:55", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma Inc (IMMX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Immix Biopharma Inc (IMMX), highlighting analyst ratings, target prices, and past EPS performance. Five analysts currently rate IMMX as a \"Buy\" with a target price of $21.00, suggesting a 130.01% upside. The report also lists peer co", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-immx/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T08:40:52", "published_display": "18 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma Inc (IMMX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Immix Biopharma Inc (IMMX) focusing on its dividend history and stock splits. The data presented indicates that the company has not distributed any dividends over the past five years and has no recorded stock split history. The article also in", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-immx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T08:09:47", "published_display": "18 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma Inc (IMMX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey focuses on Immix Biopharma Inc (IMMX) and its revenue breakdown. It states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The page provides basic stock information ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-immx/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T01:09:15", "published_display": "18 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMX Initiates Coverage On LifeSci Capital -- Rating at Outperfo", "summary": "LifeSci Capital initiated coverage on Immix Biopharma (IMMX) with an \"Outperform\" rating and a $19.00 price target, suggesting significant upside from its current trading price of $9.31. Despite a low GF Score\u2122 of 30/100, indicating weaknesses in profitability and growth, IMMX bo", "url": "https://www.gurufocus.com/news/8921236/immx-initiates-coverage-on-lifesci-capital-rating-at-outperform", "source_name": "GuruFocus", "published_at": "2026-06-17T20:09:15", "published_display": "17 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma Inc (IMMX) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a brief overview of Immix Biopharma Inc's (IMMX) stock performance and valuation metrics. It notes that key valuation data such as P/E, P/B, P/S, and P/CF ratios have not yet been disclosed by the company. The article also includes current stock price inform", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-immx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T16:09:15", "published_display": "17 Jun 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma Inc (IMMX) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Immix Biopharma Inc (IMMX), analyzing its volatility, financial risk, and investment risk. It details various metrics such as Beta, VaR, Maximum Drawdown, Volatility, and Return-to-Drawdown Ratio over different periods. The purpose is t", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-immx/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-17T15:41:05", "published_display": "17 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street analysts see a 120.59% upside in Immix Biopharma (IMMX): Can the stock really move this high?", "summary": "This article discusses the significant upside potential that Wall Street analysts see in Immix Biopharma (IMMX), projecting a 120.59% price increase. It poses a question regarding the feasibility of this substantial stock movement. The content originally came from an MSN source.", "url": "https://www.msn.com/en-us/money/topstocks/wall-street-analysts-see-a-120-59-upside-in-immix-biopharma-immx-can-the-stock-really-move-this-high/ar-AA24c6vs?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-09T04:39:37", "published_display": "09 Jun 2026 04:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMMX - Immix Biopharma Inc Stock Price and Quote", "summary": "This page provides a comprehensive overview of Immix Biopharma Inc. (IMMX) stock, including its latest stock price, financial data, performance metrics, and recent news and analyst ratings. It also details insider transactions, highlighting purchases by the CEO and CFO, and lists", "url": "https://finviz.com/stock?t=IMMX", "source_name": "Finviz", "published_at": "2026-06-07T04:09:51", "published_display": "07 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janus Henderson files 13G/A: 9.09M shares of Immix Biopharma (IMMX)", "summary": "Janus Henderson Group plc has filed an amended Schedule 13G/A, reporting beneficial ownership of 9,090,732 shares, or 13.0% of Immix Biopharma, Inc. (IMMX). The filing indicates that Janus Henderson's Asset Managers exercise shared voting and dispositive power over these shares, ", "url": "https://www.stocktitan.net/sec-filings/IMMX/schedule-13g-a-immix-biopharma-inc-amended-passive-investment-disclos-58e09dfc31b7.html", "source_name": "Stock Titan", "published_at": "2026-06-05T16:40:19", "published_display": "05 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma, Inc. Files Form 8-K Announcing Election of Directors and Corporate Details (May 2026)", "summary": "Immix Biopharma, Inc. (NASDAQ: IMMX) has filed its Form 8-K to announce the results of its 2026 Annual Shareholder Meeting held on May 22, 2026. Shareholders elected Ilya Rachman as a director with strong approval and ratified Crowe LLP as the independent registered public accoun", "url": "https://www.minichart.com.sg/2026/05/31/immix-biopharma-inc-files-form-8-k-announcing-election-of-directors-and-corporate-details-may-2026/", "source_name": "Minichart", "published_at": "2026-05-31T09:08:57", "published_display": "31 May 2026 09:08", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma (IMMX) director receives 6,250 RSUs and 12,500 options", "summary": "Immix Biopharma director Nancy T. Chang received equity awards totaling 6,250 restricted stock units (RSUs) and options for 12,500 shares. These awards, granted under the 2021 Equity Incentive Plan, are subject to vesting schedules tied to continued service and the company's 2027", "url": "https://www.stocktitan.net/sec-filings/IMMX/form-4-immix-biopharma-inc-insider-trading-activity-39f650a73b1e.html", "source_name": "Stock Titan", "published_at": "2026-05-30T12:10:59", "published_display": "30 May 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma (IMMX) CFO, President awarded 500,000 stock options at $8.78", "summary": "Immix Biopharma's CFO and President, Morris Gabriel S, was granted 500,000 stock options with an exercise price of $8.78 per share, expiring on May 22, 2036. The options vest in 48 equal monthly installments, linking the executive's ownership to continued service. This grant is c", "url": "https://www.stocktitan.net/sec-filings/IMMX/form-4-immix-biopharma-inc-insider-trading-activity-c6e217c25eb4.html", "source_name": "Stock Titan", "published_at": "2026-05-30T12:08:57", "published_display": "30 May 2026 12:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma (IMMX) director Carey Ng awarded RSUs, 12,500-share option", "summary": "Immix Biopharma director Carey Ng received 6,250 restricted stock units (RSUs) and a stock option for 12,500 shares. The RSUs will vest on the earlier of one year from the grant date or the 2027 annual stockholders' meeting, while the stock option vests in monthly installments ov", "url": "https://www.stocktitan.net/sec-filings/IMMX/form-4-immix-biopharma-inc-insider-trading-activity-882d4d8d6294.html", "source_name": "Stock Titan", "published_at": "2026-05-30T12:08:57", "published_display": "30 May 2026 12:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma (IMMX) awards CEO 500,000 stock options at $8.78 strike", "summary": "Immix Biopharma, Inc. (IMMX) has granted its CEO and Chairman, Ilya M. Rachman, 500,000 stock options with an exercise price of $8.78 per share, expiring on May 22, 2036. These options serve as compensation and will vest in 48 equal monthly installments, contingent on Dr. Rachman", "url": "https://www.stocktitan.net/sec-filings/IMMX/form-4-immix-biopharma-inc-insider-trading-activity-2fdd731ceef8.html", "source_name": "Stock Titan", "published_at": "2026-05-29T21:10:23", "published_display": "29 May 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNdTRSUkpvZDZJb2lMendCYlFteTlGU3hiWC1OMGlWNm1jNnZkdGJ1RVY0WFJyOG90QlBnMHFnRlhHYlhfdkhzSmhKengyS2dDeTVzbXZlOVdsbFo5TWYtNTNHLVdOQXpMOGlKb3V4dkFfV0xJMlQ0Y2UzTGxBek9hRDJpaE1rTXhieHAxeGlQVHNSN29xSVpwZ0pmNkhpMmdtSld3cVJnckNiTEs1SGd2MU1fUQ?oc=5", "source_name": "Investing News Network", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma, Inc. Closes $140.65 Million Underwritten Registered Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNa3czaUNvMzh4bG9Fd18tZTlxQnU1cXdMYld5X3RCRGtSWEZjeTlIX0s5T3A5UW1wclYtaDhIdkJmc0RjUEtxaG9CVGNIbHkybDhBMVo5Nzc4U2pzYXBrV1l2R0lib2hnX3JYbGJDTlEzOU4wbEw1UTJmT3lEa01KbzlQTDBKY0xMeWcxemVQVmdfMXdNVGZtUkpXNHNOel9CdTVzNnNMbERxWjJIckEyMk9QdWxBNU9EbDkxOHR5UzJyNXNLcklfblhn?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma Prices $150 Million Stock Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immix-biopharma-prices-150-million-110608655.html", "source_name": "MT Newswires", "published_at": "2026-05-21T11:06:08+00:00", "published_display": "21 May 2026 11:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma Reports 95% Complete Response Rate in AL Amyloidosis Trial", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/immix-biopharma-reports-95-complete-104403227.html", "source_name": "MT Newswires", "published_at": "2026-05-21T10:44:03+00:00", "published_display": "21 May 2026 10:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxORENuS0NMcWk3SjlNRy0xSnNkX0ZRQUlLbDVYT3pVb3J6V0pZQWFnUkRtN2VZOF9welVjODdGaGpRejBnVm5nZnBBRE5oRE9qbzUxaFZZcWpFTVZ1S3ZFNUNsVzZXLTlrbWs0V0QwSTNJMzFYeW44TE5Dbl9pMG9MM2VxYmZGcVlBVTFVZ1RWX3BQMzBBQ05mbW5JS0F5SWtaakk3SW51a1J4ZEVMSmwzQllldw?oc=5", "source_name": "Investing News Network", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma prices $150M deal to fund NXC-201 work into 2028", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOZFJRcFF5SHZETVluZUpnV0x3OTlXM1NDRXlvNnJtVHRpaklNRWNycnA4MWxsYjZONzRnV09fUzYxUkl5eWc4eWhFaEJoR3l5VktfTVdOM3g3cV9uRmR0VUllYU1ZVkJCdTFDeGJZRDdGWUY5akdFaVdrYVdZbVlXZFA1MWhmSDNXYk1oeWpvZUtFc2o0LWtUYUNsMWhkY1Z0b2VZYmV4TWZsMkxyT3ZMbENVQTlVdXM?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix rises after mid-stage trial data for AL amyloidosis therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPcGNReUVmcE5xZG9qcFYzbktGbTBqMFNXOVEwbnhCOVRQbWhCbUpFaktjaUxsekxJZXlLeUZJdVNhZ1lFbUh3WmlaUTR4bXNyNkZDYTBWRVluWnpRVXBpalJMWFlDaFk0YV9Hb3ZhMVNialJLUFF1c2pBSE5TVjFWaTI3VQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma stock rating maintained at Market Outperform by Citizens", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQaEV5OXlVRWVMbFBtMGNxa0hreEExYUM2cnFtc0p2ZlJQTWc3dU9RaFpzdE92bGZBZzBEMjhGdmtqcld4Q3plWkRlNzN1WEJsbERDVTY4N0pycDlYVWhiaTJmNU03WHVWOEYzbXpyWmRfRzBlS1JzSTFQamZKWFZraVRZNUpTZm9BNnJKR3pkcWtFcWtNZVEyZkluMVItT2xfdmEyNjJkejZXWXJrUUl6SVROSWVicGtZWVZYS040b2VINmd4VDJTQVRQM0s?oc=5", "source_name": "Investing.com", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Immix Biopharma (NASDAQ:IMMX) Can Afford To Drive Business Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOVnVWc0UwUmljcHBnd0dHSzM1QTlUeVdGOWx1aUw5R3F0bjBLYzhwY09keVFBUG9NWUYwaWJYYnBtejNIS3QteGxSdnk2UXR6T2hJVkVYTjZjZVZqMnpxOTlJZ2RvUUx3LWd4cE5PVzJoZmRzRExZQ1RHUUxFWEV4Qmp1MHI0dGVUUElLX1dtUzVtcjZEd3dqRHloTnhnOW8?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Immix Biopharma (IMMX) One of the Best Performing NASDAQ Stocks?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNazR1UHNhcDRqRGh3cFU4eVl3ZWNrYWQ3aGxiWUpFMUVjZlBFV183XzFwRjdFZ3BlQ2FDQWNCQUFCaHhpbEZOR3NJdzJ0RDNOb2d4Nzh4OG1QU3d4YlNxSWNjR1pDMzlzeFFvVngzUkJrem9TQmp6TFlWYjRzUDNFOXhXT1ZtZmgyRktGeWJFMjk4Y2tMRWk1MFNR?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma lines up investor meetings at Jefferies event", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPSWhVNXNtU1BtdDRuMVRtdElUd3FQTERqMmRjTlZSREhfc3NoYWtoaWZ3VEpWekZ0bGh1ZVAxcldEbXNPWkVHTUROVDgzMWZSald3NTRHNHNfaFNVblhjVXluQjdQRnVXaS14S2RMTnFEeW8wblFHUFl2QjhVWjNmZW9sLUlnSnY1dk5WWmlJdWl5T29QdG5MaTNROGZGOEg3TS03d2tyZFZnMHdPSFhKWHVUNVU4Z0Y1Mk4yQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix fills amyloidosis trial; Q3 results tee up planned FDA filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNTTJlOVd5ekdZeVBvcFBDNldtYUxQd0EyQWMzNS1mcWFMTmFlMFlaMEhZQ0RyLTdTZXBvZnR1WXhpOFF1WDZTVjc5d2kwdmx4dzhXT0Q1RmZMX1JCc3o3RVJUYnpIY0h3NWRGN0VTS0lyaGxsZmV6SDJXSDhOSlFjdG81LVF4d1A5WGJIRjVaMThVbF83aTY2QlJVZTdXdnFjWkdPcEpGQndwVmFHTnFLT1hEeUZIQlhjRkE?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma (NASDAQ: IMMX) amends $100M at-the-market stock sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNLU12Sm1Qelg1RGVIRDNnTEVrZFJXeUtkTmdkR1JKczJIdVRnZ2hJRVl1MTU3ZGZndVZhWGtXS2pHM2kyNUtJV29DTzZFeERVSmFkbVFYVGprdWFZakYwWUlPMGNSSkNNTUlnSHlqbGhha1ZEQXhqMzdOeENEVDBQQUJPdWdmRGw0bm1mSVpEbGxxMm1WSVI5UHVvSmpyTUFLRy1PdHBhbkRaQmd2?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Expect Breakeven For Immix Biopharma, Inc. (NASDAQ:IMMX) Before Long", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma, Inc. Closes $93.7 Million Underwritten Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNZ2Z5ZkxEMTdhaVlXa2F2Rm9aZkxnS0RhdzIwZEJsbVJlSENucnFjZzZMU2lXZjEwX0d4VHlKODZKekhzQk5DUnl0djlqQkVDem16a2xnbDljYTRIY2o4WUNpRm5qY05WZ2tReFpETnNRMEpVNF9jQ25CbmM1RHNOSkF5R3NNUm1tZ0EtVWJraVJQMFpIMUZjY09OUXEyTGRuZ0sxOF80NTc3ZEZzUU9yaUJyU01mNTB3dGVuM3NGUk1hOVllbGl0VmUtUERQd01uQ3lOWFdSSjk?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immix Biopharma (IMMX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBzVmlWM2M0ZG12NVdnc2JONnBTTHd4a0tFSEQ5SXpOdGNLZkpEaFhOX1BWdy1kUzdmUmMtOWpkTU85aHVOR2VaSjREVzRGN1hwYVhLWVVZSjFQdw?oc=5", "source_name": "MarketBeat", "published_at": "2021-12-17T00:51:18+00:00", "published_display": "17 Dec 2021 00:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 90, "total_relevant": 54, "sentiment_summary": {"positive": 17, "negative": 1, "neutral": 36, "score": 57, "total": 54, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 13.0, "count": 23}, {"event": "earnings", "label": "Earnings", "weight": 8.8, "count": 18}, {"event": "analyst", "label": "Analyst action", "weight": 5.5, "count": 10}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 17, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 11.11, "latest_week": "2026-07-10", "one_week_move": 7.4, "four_week_move": 31.5, "twelve_week_move": 7.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.086093, "market_dynamics_buy_signal": false, "relative_strength": 60.766825, "fair_value_gap": 194.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 53.5363, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+7.4% over one week, +31.5% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 65, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 9}, {"label": "TradingView", "count": 9}, {"label": "Stock Titan", "count": 9}, {"label": "TradingKey", "count": 5}, {"label": "MT Newswires", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Investing News Network", "count": 2}, {"label": "Quiver Quantitative", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 46}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 23}, {"label": "Earnings", "count": 18}, {"label": "Analyst action", "count": 10}, {"label": "Regulatory and legal", "count": 1}, {"label": "Capital return", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "46", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+7.4% over one week, +31.5% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Immix Biopharma Inc. (IMMX) Stock Price | Live Quotes & Charts | NASDAQ"}], "updated_at": "2026-07-16T11:42:30.494014+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}